InvestorsHub Logo
Followers 35
Posts 1393
Boards Moderated 0
Alias Born 09/09/2009

Re: None

Monday, 12/03/2012 3:53:19 PM

Monday, December 03, 2012 3:53:19 PM

Post# of 3072
this is their other subsidiary....
We’re taking aim at chronic disease and we won’t give up until we conquer.

Biospherics, a wholly owned subsidiary of Spherix Incorporated, is a leader in the application of chiral carbohydrate chemistry and research in the metabolic syndrome. The Company’s new lead candidate is SPX-106T, a therapeutic combination licensed from the college of pharmacy for reducing triglycerides, cholesterol and atherosclerosis. Biospherics also has phase 3 clinical trial results with D-tagatose, a naturally occurring, simple sugar being developed as an oral treatment for glycemic control in patients with Type 2 diabetes.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDXC News